| Name | Title | Contact Details |
|---|
UPM Pharmaceuticals is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Flexicare is a privately owned, leading manufacturer and supplier of medical devices with over 40 years of experience in the healthcare sector. With over 40 years of experience in the design, development and manufacture of medical devices, Flexicare ha...
illumiPure’s patented Air Guardian and CleanWhite product solutions provide continuous and powerful disinfection to safely eradicate surface and air pathogens, as well as viruses, including SARS-CoV-2, the virus that causes COVID-19, while continuously...
Locus Pharmaceuticals, Inc. is a world leader in fragment-based, computational drug design. We have combined highly integrated chemistry, crystallography and biology capabilities to create a unique drug design and development platform for oral drug